SBIR TOPIC 425 PHASE I: POSTURE ANALYSIS THROUGH MACHINE LEARNING (PATHML)

SBIR 主题 425 第一阶段：通过机器学习进行姿势分析 (PATHML)

• 批准号: 10931985
• 负责人: ARFAAN RAMPERSAUD
• 金额: $ 35.5万
• 依托单位: COLUMBUS NANOWORKS, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-02-27 至 2024-02-26
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10931985
• 关键词: Biological Markers; Breast Cancer Patient; Cancer Patient; Comparative Study; Complement; Consensus; Data; Detection; Development; Diagnostic; Diagnostic tests; Diamond; Life; Machine Learning; Magnetic nanoparticles; Magnetometries; Methods; MicroRNAs; Monitor; Nitrogen; Optics; Paraffin Embedding; Pattern; Performance; Phase; Posture; RNA Sequences; Reporting; Research; Reverse Transcriptase Polymerase Chain Reaction; Small Business Innovation Research Grant; Specific qualifier value; Technology; Time; Tissue Embedding; Untranslated RNA; advanced breast cancer; aggressive breast cancer; cancer biomarkers; detection limit; inflammatory breast cancer; magnetic field; molecular marker; nanodiamond; point of care; predictive signature; quantum

Inflammatory breast cancer, (IBC), is a rare and highly aggressive subtype of advanced breast cancer. Small, non-coding RNAs, microRNAs or miRs, are molecular biomarkers for IBC although there is no consensus miR pattern for IBC. RT-PCR, the gold standard for miR profiling, has identified a 5-miR signature predictive of IBC aggressiveness. Other technologies are still needed that can confirm these results and complement (or even supplant) RT-PCR methods. This project will use Diamond Magnetometry (DM) as an advanced quantum-based, all-optical technology for rapid, ultrasensitive sensing of molecules. DM uses fluorescent, nitrogen-vacancy center nanodiamonds (FNDs) to sense/detect very weak magnetic fields. In Objective 1, we will exploit FNDs and magnetic nanoparticles to detect three of the five miR biomarkers of IBC using a microchannel format. In Objective 2, we will determine performance parameters for DM and demonstrate the technology using FFPE from normal and breast cancer patients. This will include a comparison of DM to RT-PCR. Sensing miR targets with DM will be transformative and radically alter how we use and monitor cancer biomarkers. Development of this quantum-based technology will reduce diagnostic testing time from days to minutes, and make real-time, point of care possible, saving money, time, and lives.

炎症性乳腺癌（IBC）是一种罕见且高度侵袭性的晚期乳腺癌亚型。小的非编码 RNA、microRNA 或 miR 是 IBC 的分子生物标志物，尽管 IBC 没有一致的 miR 模式。 RT-PCR 是 miR 分析的黄金标准，已鉴定出可预测 IBC 侵袭性的 5-miR 特征。仍然需要其他技术来证实这些结果并补充（甚至取代）RT-PCR 方法。该项目将使用金刚石磁力计 (DM) 作为一种先进的基于量子的全光学技术，用于快速、超灵敏的分子传感。 DM 使用荧光氮空位中心纳米金刚石 (FND) 来感测/检测非常弱的磁场。在目标 1 中，我们将利用 FND 和磁性纳米颗粒以微通道形式检测 IBC 的 5 种 miR 生物标志物中的 3 种。在目标 2 中，我们将确定 DM 的性能参数，并使用来自正常和乳腺癌患者的 FFPE 演示该技术。这将包括 DM 与 RT-PCR 的比较。通过 DM 检测 miR 靶点将带来变革，并从根本上改变我们使用和监测癌症生物标志物的方式。这种基于量子的技术的开发将把诊断测试时间从几天缩短到几分钟，并使实时护理成为可能，从而节省金钱、时间和生命。